Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 11/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18278480 | 0.89 | MAPK8 (0.35) | JAK2TBK1ACVR1 | |
| SCHEMBL18277789 | 0.87 | TBK1 (0.38) | JAK2TBK1ACVR1FGFR1KDR | |
| SCHEMBL18278484 | 0.87 | JAK2 (0.36) | JAK2TBK1ACVR1 | |
| SCHEMBL18278543 | 0.86 | JAK2 (0.38) | JAK2TBK1ACVR1FGFR1KDR | |
| SCHEMBL18278644 | 0.86 | JAK2 (0.38) | JAK2TBK1ACVR1FGFR1KDR | |
| SCHEMBL18278490 | 0.85 | MAPK8 (0.39) | JAK2TBK1ACVR1POLBMAPT | |
| SCHEMBL18278687 | 0.85 | MAPT (0.39) | JAK2TBK1ACVR1FGFR1KDR | |
| SCHEMBL18278681 | 0.84 | JAK2 (0.37) | JAK2TBK1ACVR1FGFR1KDR | |
| SCHEMBL18278323 | 0.84 | ACVR1 (0.36) | JAK2TBK1ACVR1FGFR1KDR | |
| SCHEMBL18278638 | 0.84 | USP2 (0.37) | JAK2TBK1ACVR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-06 | — | — | US | claimed |
| EP-3302465-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016197009-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | WO | claimed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-06 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | PMP22, MYT1, IKZF3 | JAK2 1773/4885TBK1 182/4885ACVR1 3450/4885 |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | JAK2 1773/4885TBK1 182/4885ACVR1 3450/4885 |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | PMP22, MYT1, IDE | JAK2 3034/4885TBK1 944/4885ACVR1 3432/4885 |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | JAK2 1773/4885TBK1 182/4885ACVR1 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.